USPTO’s Lax Policy Leads to Humira Formulation Thicket

Journal of Law, Medicine and Ethics 52 (2):429-438 (2024)
  Copy   BIBTEX

Abstract

Biosimilar drugs enter the United States market well after they enter the European market. That is likely because pharmaceutical companies have many more patents in the United States than in Europe. But why is patent coverage of biological drugs so much more extensive in United States? This case study seeks to answer this question for drug formulation patents.

Categories

Keywords

Reprint years

DOI

10.1017/jme.2024.132

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 100,440

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Why are Generic Drugs Being Held up in Transit? Intellectual Property Rights, International Trade, and the Right to Health in Brazil and beyond.Mônica Steffen Guise Rosina & Lea Shaver - 2012 - Journal of Law, Medicine and Ethics 40 (2):197-205.
A Consequentialist Examination of the Circumvention of the Public Will in U.S. Genetic and Biotechnology Law.Adam T. Goodstone - 2013 - Binghamton Journal of Philosophy 1 (1):67-86.
Can drug patents be morally justified?Dr Sigrid Sterckx - 2005 - Science and Engineering Ethics 11 (1):81-92.
Using Patent Data to Assess the Value of Pharmaceutical Innovation.Aaron S. Kesselheim & Jerry Avorn - 2009 - Journal of Law, Medicine and Ethics 37 (2):176-183.
Can drug patents be morally justified?Sigrid Sterckx - 2005 - Science and Engineering Ethics 11 (1):81-92.
The european patent convention.Justine Pila - unknown
Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation. [REVIEW]Sarosh Nagar & Aaron S. Kesselheim - 2021 - Journal of Law, Medicine and Ethics 49 (4):683-687.
Generic drug competition: The pharmaceutical industry “gaming” controversy.Thomas A. Hemphill - 2019 - Business and Society Review 124 (4):467-477.
Pharmacogenetics and Pharmacogenomics: Public Policy and Bioethical Issues Associated with Patents for Drug Development.Arthur Falek & Michael W. Jann - 2000 - Global Bioethics 13 (3-4):29-42.

Analytics

Added to PP
2024-10-23

Downloads
4 (#1,799,420)

6 months
4 (#1,238,277)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references